

AnnaBidiol Corp.
A Delaware Corporation
(617) 517-6310

For the Three and Nine Months Ended September 30, 2024, and 2023

Prepared in accordance with
OTC Pink Basic Disclosure Guidelines

TABLE OF CONTENTS

	<u>Page</u>
Forward Looking Statements	3
Organizational Structure	3
Management	3
Balance Sheets as of September 30, 2024, and December 31, 2023	4
Statements of Operations for the Three and Nine Months Ended September 30, 2024, and 2023	5
Statement of Stockholders' Equity for the Three and Nine Months Ended September 30, 2024, and 2023	6
Statements of Cash Flows for the Nine Months Ended September 30, 2024, and 2023	7
Notes to the Financial Statements	8
OTC Pink Basic Disclosures	11
Signatures	15

Forward-Looking Statements

This Company Profile contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made herein that may be considered forward-looking include statements incorporating terms such as "expects," "believes," "intends," "anticipates," and similar terms that relate to future events, performance, or results of the Company, including without limitation, statements made regarding expected future results. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from management's present expectations or projections. These risks and uncertainties include but are not limited to, customer and supplier relationships; prices; competition; ability to realize anticipated benefits from initiatives taken; market demand; litigation and other liabilities; and economic, political, governmental, and technological factors affecting the Company's operations, tax rate, markets, products, services, and prices, among others.

Organizational Structure

AnnaBidiol Corp. (the "Company" or "Asiana") was incorporated in the State of Delaware on Sept. 22, 2009, as DragonTel Holding, Inc., which thereafter changed its name to Asiana Dragons, Inc. The Company again changed its name to Strategic Pharma Information Sciences, Inc. on July 25, 2016, and then to AnnaBidiol Corp., effective upon FINRA approval on January 8, 2018.

Management

David D Peralta - Mr. Peralta has served as the President and sole Director of the Company since December 9, 2019. He was appointed interim Chief Executive Officer, effective October 30, 2023.

ANNABIDIOL CORP.
UNAUDITED BALANCE SHEETS

	<u>September 30, 2024</u>	<u>December 31, 2023</u>
ASSETS		
Current Assets		
Cash	3,370	9,931
Total Current Assets	<u>3,370</u>	<u>9,931</u>
Total Assets	<u><u>\$ 3,370</u></u>	<u><u>\$ 9,931</u></u>
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current Liabilities		
Accounts payable and accrued expenses	\$ 198,872	\$ 191,121
Total Liabilities	<u>198,872</u>	<u>191,121</u>
Commitments and Contingencies	-	-
Stockholders' Deficit		
Preferred Series A, \$0.0001 par value; 5,000,000 shares authorized, 500,000 shares issued and outstanding as of September 30, 2024, and December 31, 2023	50	50
Common Stock, \$0.0001 par value; 495,000,000 shares authorized, 39,990,306 shares issued and outstanding as of September 30, 2024, and December 31, 2023	3,999	3,999
Subscription payable	-	-
Additional paid-in capital	5,361,121	5,361,121
Accumulated deficit	<u>(5,560,672)</u>	<u>(5,546,360)</u>
Total Stockholders' Deficit	<u>(195,502)</u>	<u>(181,190)</u>
Total Liabilities and Stockholders' Deficit	<u><u>\$ 3,370</u></u>	<u><u>\$ 9,931</u></u>

The accompanying notes are an integral part of these consolidated financial statements.

ANNABIDIOL CORP.
UNAUDITED STATEMENTS OF OPERATIONS

	For the Three Months Ended		For the Nine Months Ended	
	September 30, 2024	September 30, 2023	September 30, 2024	September 30, 2023
Revenue	\$ -	\$ -	\$ -	\$ 10,000
Cost of Goods Sold	-	-	-	-
Gross Profit	-	-	-	10,000
Operating Expenses:				
General administrative	2,971	1,635	13,312	11,695
Professional and consulting fees	-	-	1,000	5,000
Travel	-	-	-	-
Total operating expenses	2,971	1,635	14,312	16,695
Loss from operations	(2,971)	(1,635)	(14,312)	(6,695)
Other Income (Expense)				
Interest expense	-	-	-	-
Total other income (expense)	-	-	-	-
Net Loss Before Income Taxes	(2,971)	(1,635)	(14,312)	(6,695)
Income tax	-	-	-	-
Net Loss After Income Taxes	\$ (2,971)	\$ (1,635)	\$ (14,312)	\$ (6,695)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	39,950,306	39,984,654	39,950,306	39,961,881
Loss per Common Share - Basic and Diluted	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)

The accompanying notes are an integral part of these consolidated financial statements.

ANNABIDIOL CORP.
UNAUDITED STATEMENTS OF STOCKHOLDERS' DEFICIT

	Shares Outstanding Preferred A	Preferred A	Shares Outstanding Common	Common Stock	Subscription Payable	Additional Paid-In Capital	Accumulated Deficit	Total Stockholders' Deficit
Balance as of June 30, 2023	500,000	\$ 50	39,950,306	\$ 3,995	\$ 20,000	\$ 5,318,125	\$ (5,541,390)	\$ (199,220)
Issuance of common stock	-	-	40,000	4	(20,000)	19,996	-	-
Contributions by majority shareholder	-	-	-	-	-	(2,000)	-	(2,000)
Net loss	-	-	-	-	-	-	(1,635)	(1,635)
Balance as of September 30, 2023	<u>500,000</u>	<u>\$ 50</u>	<u>39,990,306</u>	<u>\$ 3,999</u>	<u>\$ -</u>	<u>\$ 5,336,121</u>	<u>\$ (5,543,025)</u>	<u>\$ (202,855)</u>
Balance as of December 31, 2022	500,000	\$ 50	39,950,306	\$ 3,995	\$ 20,000	\$ 5,265,625	\$ (5,536,330)	\$ (246,660)
Issuance of common stock	-	-	40,000	4	(20,000)	19,996	-	-
Contributions by majority shareholder	-	-	-	-	-	50,500	-	50,500
Net income	-	-	-	-	-	-	(6,695)	(6,695)
Balance as of September 30, 2023	<u>500,000</u>	<u>\$ 50</u>	<u>39,990,306</u>	<u>\$ 3,999</u>	<u>\$ -</u>	<u>\$ 5,336,121</u>	<u>\$ (5,543,025)</u>	<u>\$ (202,855)</u>
	Shares Outstanding Preferred A	Preferred A	Shares Outstanding Common	Common Stock	Subscription Payable	Additional Paid-In Capital	Accumulated Deficit	Total Stockholders' Deficit
Balance as of June 30, 2024	500,000	\$ 50	39,990,306	\$ 3,999	\$ -	\$ 5,361,121	\$ (5,557,701)	\$ (192,531)
Net loss	-	-	-	-	-	-	(2,971)	(2,971)
Balance as of September 30, 2024	<u>500,000</u>	<u>\$ 50</u>	<u>39,990,306</u>	<u>\$ 3,999</u>	<u>\$ -</u>	<u>\$ 5,361,121</u>	<u>\$ (5,560,672)</u>	<u>\$ (195,502)</u>
Balance as of December 31, 2023	500,000	\$ 50	39,990,306	\$ 3,999	\$ -	\$ 5,361,121	\$ (5,546,360)	\$ (181,190)
Net income	-	-	-	-	-	-	(14,312)	(14,312)
Balance as of September 30, 2024	<u>500,000</u>	<u>\$ 50</u>	<u>39,990,306</u>	<u>\$ 3,999</u>	<u>\$ -</u>	<u>\$ 5,361,121</u>	<u>\$ (5,560,672)</u>	<u>\$ (195,502)</u>

The accompanying notes are an integral part of these consolidated financial statements.

ANNABIDIOL CORP.
UNAUDITED STATEMENTS OF CASH FLOWS

	Nine Months Ended September 30,	
	2024	2023
Cash Flows from Operating Activities		
Net income (loss)	\$ (14,312)	\$ (6,695)
Changes in operating assets and liabilities:		
Accounts payable and accrued expenses	(4,999)	(44,211)
Net Cash Used in Operating Activities	(19,311)	(50,906)
Cash Flows from Investing Activities	-	-
Cash Flows from Financing Activities		
Advances by majority shareholder	7,750	-
Advances by potential acquisition company	5,000	-
Contributions by majority shareholder	-	50,500
Net Cash Provided by Financing Activities	12,750	50,500
Net Increase (Decrease) in Cash	(6,561)	(406)
Cash, Beginning of Period	9,931	1,111
Cash, End of Period	\$ 3,370	\$ 705
Supplemental Disclosure of Cash Flow Information:		
Cash paid for interest	\$ -	\$ -
Cash paid for income taxes	\$ -	\$ -

The accompanying notes are an integral part of these consolidated financial statements.

ANNABIDIOL CORP.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
September 30, 2024

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

AnnaBidiol Corp. (the “Company” or “Asiana”) was incorporated in the State of Delaware on September 22, 2009, as DragonTel Holding, Inc., which thereafter changed its name to Asiana Dragons, Inc. The Company again changed its name to Strategic Pharma Information Sciences, Inc. on July 25, 2016, and then to AnnaBidiol Corp., effective on FINRA approval on January 8, 2018. The Company is a Delaware Corporation organized for the purpose of engaging in any lawful business.

The Company has had minimal business operations or activity since 2011, when it was associated with GJC Holdings, Inc., a wholly owned subsidiary that was divested. The subsidiary’s activities ceased in June 2011 with the liquidation of all remaining assets and liabilities.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts and valuations of intangible assets, among others. Actual results could differ from those estimates.

Management regularly reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

Concentrations and credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivable. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The cash balance may, at times, exceed federally insured limits. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.

Risk and Uncertainties

The Company operates in an industry that is subject to rapid change and intense competition. The Company’s operations are subject to significant risks and uncertainties, including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity of three months or less at the date of purchase and money market accounts to be cash equivalents. As of September 30, 2024 and December 31, 2023, the Company had \$3,370 and \$9,931 of cash and no cash equivalents, respectively.

Revenue Recognition

The Company currently has no realized revenue from operations. We account for product revenue in accordance with Accounting Standards Codification 606, Revenue Recognition, and all related interpretations. Revenue is recognized when the following criteria are met:

- Identification of the contract, or contracts, with a customer
- Identification of the performance obligations in the contract
- Determination of the transaction price
- Allocation of the transaction price to the performance obligations in the contract
- Recognition of revenue when, or as, we satisfy the performance obligation.

Any revenue received that does not yet meet the above recognition standards is recorded to unearned revenue and held as a liability until recognition occurs.

Impairment of Long-Lived Assets

The Company reviews long-lived assets, at least annually, to determine if impairment has occurred and whether the economic benefit of the asset (fair value of assets to be used and fair value less disposal cost for assets to be disposed of) is expected to be less than the carrying value. Triggering events, which signal further analysis, consist of a significant decrease in the asset's market value, a substantial change in the use of an asset, a significant physical change in the asset, a significant change in the legal or business climate that could affect the asset, an accumulation of costs significantly in excess of the amount originally expected to acquire or construct the asset, or a history of losses that imply continued loss associated with assets used to generate revenue.

Income Taxes

Income taxes are provided in accordance with ASC 740 Accounting for Income Taxes. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carryforwards. Deferred tax expense (benefit) results from the net change during the year of deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of all the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Provision for income taxes consists of federal and state income taxes in the United States. Due to the uncertainty as to the realization of benefits from our deferred tax assets, including net operating loss carryforwards and other tax credits, we have a full valuation allowance reserved against such assets. We expect to maintain this full valuation allowance, at least in the near term.

The Company records interest and penalties related to unrecognized tax benefits in income tax expense. There were no interest or penalties related to unrecognized tax benefits for the three and nine months ended September 30, 2024, and the year ended December 31, 2023.

Earnings per Share Policy

The basic computation of loss per share is based on the weighted average number of shares outstanding during the period presented in accordance with ASC 260, "Earnings Per Share." The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the period plus the common stock equivalents arising from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the period. Common stock equivalents are not included in the diluted earnings per share calculation when their effect is anti-dilutive.

Share-Based Payments and Stock-Based Compensation

Share-based compensation awards, including stock options and restricted stock awards, are recorded at estimated fair value on the applicable award's grant date, based on the estimated number of awards that are expected to vest. The grant date fair value is amortized on a straight-line basis over the time in which the awards are expected to vest or immediately if no vesting is required. Share-based compensation awards issued to non-employees for services are recorded at either the fair value of the services rendered or the fair value of the share-based payments, whichever is more readily determinable. The fair value of restricted stock awards is based on the fair value of the stock underlying the awards on the grant date, as there is no exercise price.

Recent Accounting Pronouncements

Management believes the impact of recently issued standards and updates, which are not yet effective, will not have a material impact on the Company's financial position, results of operations, or cash flows upon adoption.

NOTE 3 – STOCKHOLDERS' EQUITY

The total number of common shares authorized that may be issued by the Company is 495,000,000 shares with a par value of \$0.0001 per share. The Company is authorized to issue 5,000,000 shares of preferred Series A stock with a par value of \$0.0001 per share. The Company is authorized to issue 5,000,000 shares of preferred Series B stock with a par value of \$0.0001 per share. As of September 30, 2024, and December 31, 2023, there were 39,990,306 shares of Common Stock issued and outstanding, and 500,000 Preferred Series A shares issued and outstanding.

Between April 20, 2021, and May 18, 2021, the Company received aggregate proceeds of \$20,000 for the purchase of 40,000 shares of the Company's common stock at \$0.50 per share. These shares were issued on July 24, 2023.

Series A and Series B Preferred Stock

The outstanding shares of Series A Preferred Stock of the Company are owned by PRLTA, LLC. Such shareholder is also the controlling shareholder of the common stock. The shareholder may at some time elect to return or cancel some or all of the preferred.

Series A – There are 5,000,000 shares of this Series authorized and 500,000 shares issued and outstanding, with a deemed purchase price of \$1.00 per share, for liquidation purposes, and the shares have priority over all other preferred stock in liquidation.

Series A has supermajority voting power, voting with the common stock as one class, which is the equivalent of 60% of the common stock at all times. It cannot have the rights and privileges changed unless 75% of the shares of Series A vote to do so. There are no redemption rights, no cumulative dividends, and no conversion rights under the Series A Certificate of Designation.

Series B – There are 5,000,000 shares of this series authorized, and no shares issued and outstanding. The shares are junior to the Series A in liquidation priority but senior to all other shares. They have a deemed purchase price of \$1.00 per share for liquidation and dividends payment. Dividends are payable at 15% per annum, cumulative, in cash or common stock. The shares are convertible to common stock on a one-for-one basis, at the holder's option, or automatically, as forced conversion, if the common shares are traded at a daily closing price of \$1.00 per share or more for 45 consecutive trading days. The shares are redeemable at \$1.00 per share plus accrued and unpaid dividends on notice by the Company. A Pledge secures the shares on the assets of the Company for liquidation and merger purposes.

NOTE 4 – SUBSEQUENT EVENTS

We have evaluated all events that occurred after the balance sheet date through the date when our financial statements were issued to determine if they must be reported. Management has determined that other than disclosed, there were no additional reportable subsequent events to be disclosed.

The company entered into a merger agreement with Targatek, Inc. in October 2024. The agreement has certain conditions and contingencies that have not been met. These certain matters must be resolved or satisfied in order to proceed or cancel.

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

AnnaBidiol Corp.

PO Box 174
Marblehead, MA 01945
(617) 517-6310

info.DRSI@yahoo.com

SIC Code: 8748 - Business Consulting Services, Not Elsewhere Classified

Quarterly Report For the Period Ending: September 30, 2024 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

As of September 30, 2024, the number of shares outstanding of our Common Stock was: 39,990,306.

As of December 31, 2023, the number of shares outstanding of our Common Stock was: 39,990,306.

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934, and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities.

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets.

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

ITEM 1: Name of the issuer and its predecessors (if any)

AnnaBidiol Corp. (the “Company”) was incorporated in the State of Delaware on Sept. 22, 2009, and is currently active and in good standing in all states in which it operates. A listing of all previous names used by the Company is as follows:

AnnaBidiol Corp.	January 8, 2018 – Present
Strategic Pharma Information Sciences Inc.	July 25, 2016 – January 8, 2018
Asiana Dragons, Inc.	April 26, 2011 – July 25, 2016
DragonTel Holding, Inc.	September 22, 2009 – April 26, 2011

There have not been any trading suspension orders issued by the SEC since its inception.

There have not been any stock splits, stock dividends, recapitalizations, mergers, acquisitions, spin-offs, or reorganizations within the past 12 months, and none are currently anticipated.

The Company’s principal executive office is:
PO Box 174
Marblehead, MA 01945

Check box if the principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

ITEM 2: Security Information

Transfer Agent

Mountain Share Transfer, Inc.
service@mountainsharetransfer.com
2030 Powers Ferry Rd. SE
Suite #212
Atlanta, GA 30339
Phone: (404) 474-3110

Trading symbol: ACBD

Exact title and class of securities outstanding: Common equity
CUSIP: 03571L106
Par or Stated Value: \$0.0001
Total common shares authorized: 495,000,000 as of November 14, 2024
Total common shares outstanding: 39,990,306 as of November 14, 2024
Total number of shareholders of record: 491* as of November 14, 2024

*Shareholder of record may not include all shares held in “street name.”

Preferred Stock Series A

Par or Stated Value: \$0.0001
Total common shares authorized: 5,000,000 as of November 14, 2024
Total common shares outstanding: 500,000 as of November 14, 2024
Total number of shareholders of record: 1 as of November 14, 2024

Preferred Stock Series B

Par or Stated Value: \$0.0001
Total common shares authorized: 5,000,000 as of November 14, 2024
Total common shares outstanding: none as of November 14, 2024

Security Description:

Each of the Company's common shares has the right to one vote per share. There are currently no preemption or dividend rights attributable to the Company's common shares.

The Series A Preferred shares have Super Majority voting power, voting with the common stock as one class, the equivalent of 60% of the common stock at all times. It cannot have the rights and privileges changed unless 75% of the shares of Series A vote to do so. There are no redemption rights, no cumulative dividends, and no conversion rights under the Series A Certificate of Designation.

The Series B Preferred shares are junior to the Series A in liquidation priority but senior to all other shares. They have a deemed purchase price of \$1.00 per share for liquidation and dividends payment. Dividends are payable at 15% per annum, cumulative, in cash or common stock. The shares are convertible to common stock on a one-for-one basis, at the holder's option, or automatically, as forced conversion, if the common shares are traded at a daily closing price of \$1.00 per share or more for 45 consecutive trading days. The shares are redeemable at \$1.00 per share plus accrued and unpaid dividends on notice by the Company. A Pledge secures the shares on the assets of the Company for liquidation and merger purposes.

There have not been any material modifications to the rights of the holders of the Company's securities that have occurred over the reporting period covered by this report.

ITEM 3: Issuance History

On July 24, 2023, the Company issued 40,000 shares of the Company's common stock for aggregate proceeds of \$20,000.

ITEM 3A: Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date: December 31, 2021 Common: 39,950,306									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
7/14/2023	New	40,000	Common	\$0.50	Yes	Francis Sanders	Cash	Restricted	N/A
Shares Outstanding on Date of This Report: <u>Ending Balance</u> Date September 30, 2024, Common: 39,990,306									

ITEM 3B: Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: Yes: (If yes, you must complete the table below)

ITEM 4: Issuer's Business, Products, and Services

The Company has been focused, through an intensive campaign, on searching for asset acquisitions, strategic partnerships, joint ventures, and other objectives, among those objectives and our primary focus to invest or partner with companies that we believe are undervalued, underdeveloped, or whose growth potential is significant and potentially underappreciated and undervalued.

Under these or similar circumstances, the possibility of delivering sustainable value for our shareholders could be achievable but remains a work in progress.

Additionally, the Company provides consulting services to customers looking for potential business acquisitions.

The Company does not have any subsidiaries, parents, or affiliated companies.

ITEM 5: Facilities

The Company does not currently lease any facilities. Unless it acquires, partners, JV, or converts to a business that requires a physical location, the Company will continue to run virtual offices. We believe that a virtual present provides substantial savings as well as the opportunity to pivot our business strategy as opportunities arise.

ITEM 6: Officers, Directors, and Control Persons

Name of: Officer, Director, or Control Person	Affiliation with Company (e.g., Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding ⁽¹⁾
David D Peralta, PRLTA LLC ⁽²⁾	President, Director, and significant shareholder	PO Box174 Marblehead, MA 01945	36,820,000	Common	92.07%
David D Peralta, PRLTA LLC ⁽²⁾	President, Director, and significant shareholder	PO Box174 Marblehead, MA 01945	500,000	Preferred A	100%

(1) Based on 39,990,306 shares of common stock outstanding as of November 14, 2024.

(2) David D Peralta is the Managing Member of PRLTA, LLC

ITEM 7: Legal/Disciplinary History

None of the persons listed above in Item 6 have, in the last 10 years, been the subject of:

- 1) an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);
- 2) the entry of an order, judgment, or decree not subsequently reversed, suspended, or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person’s involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;
- 3) a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;
- 4) Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a “yes” answer to part 3 above or
- 5) an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person’s involvement in any type of business or securities activities.
- 6) a U.S. Postal Service false representation order, a temporary restraining order, or a preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S. mail.

There are no material pending legal proceedings to which the issuer is a party or of which any of their property is the subject.

ITEM 8: Third-Party Providers

Legal Counsel

Michael A. Littman, Attorney at Law
P.O. Box 1839
Arvada, CO 80001

ITEM 9: Financial Statements

A. This Disclosure Statement was prepared by:

Name: Chris Kohler Consulting, Inc.

Title: Accountant

Relationship to Issuer: Contract Accountant and Corporate Secretary

B. The following financial statements were prepared in accordance with:

IFRS

U.S. GAAP

C. These financial statements for this reporting period were prepared by:

Name: Chris Kohler Consulting, Inc.

Title: Accountant

Relationship to Issuer: Contract Accountant and Corporate Secretary

Describe the qualifications of the person or persons who prepared the financial statements: Financial and Accounting Expert with a Masters Degree in Accountancy

The issuer is providing the following financial statements:

a) Audit Letter

b) Balance Sheets as of September 30, 2024, and December 31, 2023;

c) Statements of Operations for the three and nine months ended September 30, 2024, and 2023;

d) Statement of Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2024, and 2023;

e) Statements of Cash Flows for the nine months ended September 30, 2024, and 2023;

f) Notes to the financial statements.

ITEM 10: Certification

Principal Executive Officer:

I, David D Peralta, Chief Executive Officer and Director, certify that:

1. I have reviewed the Disclosure Statements for the three and nine months ended September 30, 2024, and 2023 of AnnaBidiol Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements and other financial information included or incorporated by reference in this disclosure statement fairly present in all material respects the financial condition, results of operations, and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 14, 2024

/s/ David D Peralta

David D Peralta

Chief Executive Officer